RxDoctor Payments Data

Chuan Liang, MD

Neuroradiology · Philadelphia, PANPI 1679984793

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (59.1%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Penumbra, Inc. at 34.2% of the total. 2025 is the largest year on record at $6,368, more than ten times the $149 reported in 2021. Among neuroradiology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,536in general payments, 2019–2025

Across 212 payments — averaging $96.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$7K
  • Imperative Care, Inc$3K
  • Stryker$3K
  • Route 92 Medical, Inc.$2K
  • Microvention, Inc.$1K
  • Johnson & Johnson$1K
  • plus $3K from 6 others
$149,998in ownership & investment interests, 2019–2025

Across 3 payments — averaging $49,999 each. An ownership or investment interest held by the physician or an immediate family member.

  • Cleerly, Inc.$150K

What the payments were for

  • Consulting fees$1,8009%
  • Travel & lodging$6,59632%
  • Food & beverage$12,14059%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,536 in reported general payments places this provider in the 90th percentile of 42 neuroradiology providers in Pennsylvania.

See all neuroradiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$232,950
Medicare patients
1,356
Services billed
2,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate13$194

Paid to pharmacies, not to this prescriber.

Other neuroradiology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →